Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…Abstract Number: LB03 • ACR Convergence 2025
Transcutaneous Electrical Nerve Stimulation Effectively Reduces Pain in Fibromyalgia: A Pragmatic Cluster-Randomized Trial Embedded in Physical Therapy Practice
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain that is often exacerbated by movement. FM is associated with enhanced central pain transmission, while transcutaneous…Abstract Number: LB02 • ACR Convergence 2025
Tofacitinib Plus Glucocorticoids Can Effectively Reduce Relapse Rate in IgG4-Related Disease: A Randomized,Open-label controlled Trial
Background/Purpose: To evaluate the efficacy of tofacitinib combined with glucocorticoids (GCs) compared with GCs monotherapy in preventing relapse in patients with IgG4-related disease (IgG4-RD).Methods: Compared with glucocorticoid…Abstract Number: LB01 • ACR Convergence 2025
Low-dose Interleukin-2 Therapy in Systemic Lupus Erythematosus: a double-blind, randomised, placebo-controlled, phase IIb trial
Background/Purpose: Low-dose Interleukin-2 (Ld-IL2) has shown therapeutic effect in autoimmune diseases, particularly systemic lupus erythematosus (SLE). Various doses from 0.33 to 3.0 million units of…Abstract Number: LB22 • ACR Convergence 2025
Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency
Background/Purpose: Excessive formation and impaired clearance of Neutrophil Extracellular Traps (NETs) have been linked to autoimmune and inflammatory diseases, notably systemic lupus erythematosus (SLE). DNASE1-like…Abstract Number: LB08 • ACR Convergence 2025
Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study
Background/Purpose: PsA is a chronic, systemic, inflammatory musculoskeletal disease in which dysregulated IL-17A activity plays a pivotal role in disease pathogenesis. Izokibep (IZO) is an…Abstract Number: LB05 • ACR Convergence 2025
ER Stress-Induced ATP2A3 Drives Rheumatoid Arthritis via Activation of STING Signaling
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by persistent synovial inflammation and joint bone destruction. Endoplasmic reticulum (ER) stress plays an important role…Abstract Number: LB18 • ACR Convergence 2025
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
Background/Purpose: In systemic lupus erythematosus (SLE), IgG antibodies that target nuclear antigens (ANA) are pathogenic and part of the diagnostic criteria for SLE. Healthy individuals…Abstract Number: LB21 • ACR Convergence 2025
IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation
Background/Purpose: Recently, somatic mutations in hematopoietic stem and progenitor cells (HSPCs) have been proposed as a novel mechanism driving systemic inflammation. UBA1 somatic variants in…Abstract Number: LB13 • ACR Convergence 2025
Obinutuzumab Leads to Deep B-Cell Depletion in the Kidney Parenchyma of Patients With Lupus Nephritis: An Exploratory Analysis of the REGENCY Trial
Background/Purpose: B cells infiltrate the kidneys in lupus nephritis (LN) and likely contribute to the pathogenesis of kidney injury. The REGENCY trial (NCT04221477) showed that…Abstract Number: LB17 • ACR Convergence 2025
Circulating biomarkers for organ involvement in systemic lupus erythematosus: a series of systematic reviews and meta-analyses
Background/Purpose: Systemic lupus erythematosus (SLE) features heterogeneous clinical manifestations. The identification of biomarkers that facilitate initial disease recognition is a cornerstone of optimized clinical management.…Abstract Number: LB11 • ACR Convergence 2025
Efficacy and Safety of Telitacicept in Patients with Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study
Background/Purpose: Sjögren's disease (SjD) is a chronic autoimmune disease whose pathogenesis is associated with aberrant activation of B-lymphocytes. Telitacicept, a novel fusion protein, dually targets and…Abstract Number: LB12 • ACR Convergence 2025
Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial of an Innovative Intra-Articular Apoptotic Cell Therapy in Knee Osteoarthritis (OA): 3-Month Positive Outcomes and Identification of Responder Population (NCT06233474)
Background/Purpose: OA is a prevalent disabling disease growing globally due to aging populations and rising obesity. In primary OA, the effects of joint tissue damage accumulate with age,…Abstract Number: LB23 • ACR Convergence 2025
A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy
Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, promote tissue repair, and hold promise as a versatile therapeutic. Autologous polyclonal Tregs have a favorable…Abstract Number: LB24 • ACR Convergence 2025
Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2)
Background/Purpose: Sjögren's disease (SjD) is a systemic, heterogeneous, autoimmune disease with substantial disease burden, high unmet need, and no approved systemic treatments. B cell hyperactivity…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 2616
- Next Page »